Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1111-1118

  Price, Kimberly E ^a   Saleem, Najma ^a   Lee, Georgina ^a   Steinberg, Michael ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

BCR ABL; Philadelphia chromosome; T315I; TKI; Tyrosine kinase inhibitor

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB;

ABDOMINAL PAIN; ACNE; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTHRALGIA; BINDING SITE; BLEEDING; BONE MARROW CELL; BONE MARROW SUPPRESSION; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRY SKIN; FATIGUE; FLUID RETENTION; GENE MUTATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MINIMUM INHIBITORY CONCENTRATION; MUTAGENICITY; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; REPRODUCTIVE TOXICITY; REVIEW; SIDE EFFECT; SKIN DISEASE; SYSTEMATIC REVIEW; TERATOGENICITY; THROMBOCYTOPENIA;

EID: 84883265392     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S36980     Document Type: Review

References (23)

1. Chen Y, Wang H, Hagpo K, Cortes J. Trends in Chronic myeloid leukemia incidence and survival in the United States from 1975-2009. Leuk Lymphoma. 2013;54(7):1411-1417.
2. Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
3. Sprycel [package insert]. Princenton, NJ: Bristol-Myers Squibb; 2012.
4. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
5. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012; 87(11):1037-1045.
6. National Cancer Institute [homepage on the Internet]. Chronic Myelogenous Leukemia Treatment. Available from: http://www.cancer.gov. Accessed July 23, 2013.
7. Bosulif [package insert]. New York, NY: Pfizer Labs; 2012.
8. Iclusig [package insert]. Cambridge, MA: Ariad Pharmaceuticals; 2012.
9. National Cancer Institute [homepage on the Internet]. Childhood Acute Lymphoblastic Leukemia Treatment. Available from: http://www.cancer.gov. Accessed July 23, 2013.
10. National Cancer Institute [homepage on the Internet]. Adult Acute Lymphoblastic Leukemia Treatment. Available from: http://www.cancer.gov. Accessed July 23, 2013.
11. Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71(1):123-131.
12. Gaynor J, Chapman D, Little C, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol. 1988;6(6):1014-1030.
13. Koo HH. Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood. Korean J Pediatr. 2011;54(3):106-110.
14. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem. 2010;53(7):2681-2694.
15. Zhou T, Commodore L, Huang WS, et al. Structural Mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des. 2011;77(1):1-11.
16. O'Hare T, Shakespeare WC, Zhu XT, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:5 (401-412).
17. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367(22):2075-2088.
18. US Food and Drug Administration, Center for Drug Evaluation and Research Medical Review Iclusig® NDA 203469 Application. Available December 21, 2012. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000MedR.pdf. Accessed January 16, 2013.
19. ARIAD Pharmaceuticals. ARIAD announces initiation of randomized Phase 3 trial of Ponatinib in newly diagnosed patients with chronic myeloid leukemia [press release]. Cambridge, MA: ARIAD Pharmaceuticals; [July 27, 2012]. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1719432&highlight=. Accessed December 19, 2012.
20. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0. Bethesda, MD: National Cancer Institute; 2006. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed April 9, 2013.
21. US Food and Drug Administration, Center for Drug Evaluation and Research, Office Director Decisional Memo 203469 Iclusig® (ponatinib). Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000ODMemo.pdf. Accessed April 9, 2013.
22. Ariad Pharmacetuicals. Ariad Pipeline. Available from: http://www.ariad.com/pipeline. Accessed April 24, 2013.
23. Ren M, Qin H, Ren R, Cowell JK. Ponatinib suppresses the development of myeloid and lymphoid malignanies associated with FGFR1 abnormalities. Leukemia. 2013;27(1):32-40.